Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Sean Janzen who wrote (1180)	9/19/2000 8:34:25 PM
From: the truth	Read Replies (1) \| Respond to of 1185

Time to buy. I think Nortran is finally ready to come out with some good news concerning licensing agreements. The Tse listing is a definite positive. Especially since the listing requirements to get on the TSE have been tightened. truth

To: Sean Janzen who wrote (1180)	8/26/2002 12:43:33 PM
From: Chuca Marsh	Read Replies (1) \| Respond to of 1185

Hi George YOU are still posting but Sean is not LOOK: Thought of Cardiome # 1235 is still intrails: OK Nortran LOL] : ""A plain-text copy of the "SCIENCE News This Week" section has been appended below. If you no longer wish to receive these messages, you may modify your "Contents Awareness" profile at: sciencemag.org ----------------------------------------------------------------- SCIENCE News This Week August 23 2002, 297 (5585) NEWS OF THE WEEK ------------------- --------------------------------------------------------------------------- PHARMACOGENETICS: Gene Mutation May Boost Risk of Heart Arrhythmias (p. 1252) --------------------------------------------------------------------------- Jean Marx Researchers have already identified several mutant genes that cause rare and potentially fatal heart arrhythmias. Now, on page 1333, a team offers evidence that a different variation in one of those genes, dubbed SCN5A, might increase the risk of heart rhythm disturbances in members of the population at large, not just in those few people with the hereditary arrhythmias. The variant gene, found primarily in persons of African descent, isn't likely to cause problems on its own, but might in combination with certain medications, including some used to treat high blood pressure, that also raise the risk of heart arrhythmias. Full story at sciencemag.org "" and Cardiome's RSD1122 compound to be returned Cardiome Pharma Corp (2) COM Shares issued 28,280,598Mar 27 2002 close $ 2.86 Thursday March 28 2002News Release Mr. Bob Rieder reports CARDIOME ANNOUNCES RETURN OF RIGHTS TO RSD1122 Cardiome Pharma has received notice from AstraZeneca AB that AstraZeneca does not intend to proceed with clinical development of Cardiome's preclinical compound RSD1122. Under the terms of the licence agreement, AstraZeneca will return all rights and preclinical data associated with the compound to Cardiome. Cardiome will evaluate the AstraZeneca preclinical data and, following consultation with its board of directors and scientific advisory board, decide future plans for the preclinical drug candidate. "In light of our recent successes, this is somewhat disappointing to Cardiome," said Bob Rieder, Cardiome's president and chief executive officer. "However, our two unpartnered clinical programs are significantly more advanced, and therefore far more valuable to Cardiome, than the preclinical RSD1122 program. Our relationship with AstraZeneca remains positive and we continue to maintain a dialogue with them on other potential partnership opportunities." "As far as we know, AstraZeneca's decision regarding RSD1122 was based on difficulties associated with manufacturing and pharmacokinetic issues," stated Dr. Alan Ezrin, Cardiome's chief scientific officer. "Cardiome's atrial arrhythmia drug RSD1235 targets a different biological mechanism, has no significant manufacturing issues, and has pharmacokinetic properties compatible with acute and chronic management of atrial fibrillation." Cardiome is currently completing a 60-patient phase 2 clinical trial of RSD1235, for conversion of atrial arrhythmia to normal heart rhythm. The study is being conducted at 20 sites in the United States and Canada. Through its recent acquisition of Paralex, Inc., Cardiome is also developing oxypurinol for treatment of congestive heart failure. Cardiome intends to begin a phase 2 clinical trial with oxypurinol in the second half of 2002. WARNING: The company relies upon litigation protection for "forward-looking" statements. (c) Copyright 2002 Canjex Publishing Ltd. stockwatch.com old url (better for printing) Chucka